HARMONY BIOSCIENCES HOLDINGS (HRMY)       52.74  +1.97 (+3.88%)

52.74  +1.97 (+3.88%)

US4131971040 - Common Stock

HARMONY BIOSCIENCES HOLDINGS52.74

NASDAQ:HRMY (8/10/2022, 2:08:04 PM)+1.97 (+3.88%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-02 2022-08-02/bmo Earnings (Next) 11-07 2022-11-07/bmo
Ins Owners 0.43% Inst Owners 78.85%
Market Cap 3.11B Shares 59.05M
PE 47.51 Fwd PE 15.51
Dividend Yield N/A Analysts 84.62
IPO 08-19 2020-08-19

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

HRMY Daily chart

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 180 full-time employees. The company went IPO on 2020-08-19. The Company’s operations are conducted through its wholly owned subsidiary, Harmony Biosciences, LLC (Harmony). The firm is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with neurological disorders. The firm's product WAKIX (pitolisant), is a molecule with a novel mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and is the narcolepsy treatment that works primarily through histamine, which is a neurotransmitter. The firm also provides HBS-102, an investigational compound, is a melanin-concentrating hormone (MCH) receptor 1(MCHR1) antagonist that targets MCH neurons in the brain.

Company Info

HARMONY BIOSCIENCES HOLDINGS

630 W Germantown Pike, Suite 215

Plymouth Meeting PENNSYLVANIA 19462

P: 14845399800.0

CEO: John C. Jacobs

Employees: 180

Website: https://www.harmonybiosciences.com/

News

News Image5 days ago - Investor's Business DailyStock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

News Image8 days ago - Investor's Business DailyHarmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat

Shares surged well above the 5% chase zone in early action Tuesday.

News Image8 days ago - Harmony BiosciencesHarmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates

WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021 Average Number of Patients on WAKIX...

News Image22 days ago - BusinessInsiderHARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS

PLYMOUTH MEETING, Pa., July 19, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ('Harmony' or the 'Company') (Nasdaq: HRMY), a pharmaceuti...

News Image22 days ago - Harmony BiosciencesHARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...

HRMY Twits

Here you can normally see the latest stock twits on HRMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example